Fangda, JunHe on dual listed biomedicine maker’s application for Shanghai’s STAR Market triple listing
Fangda Partners is advising BeiGene, a Chinese biopharmaceutical company listed in Nasdaq and HKEx, on its planned listing in Shanghai Stock Exchange’s STAR Market, with JunHe advising the joint sponsors.
Established in 2010, the Beijing-headquartered BeiGene focuses on developing molecularly targeted and immuno-oncology drug candidates for the treatment of cancer. BeiGene launched its IPO in Nasdaq in 2016 and was later listed in Hong Kong in 2018, becoming the first US and HK dual listed Chinese biopharmaceutical company. If successfully listed in STAR Market, the company will become the first of its kind to be triple listed.
According to the prospectus, the Fangda team is led by partners Ding Jidong, Liu Yiwei and Fang Yuan, and the JunHe team is led by partners Yu Yongqiang and Tao Xudong.
The joint sponsors are CICC and Goldman Sachs.
To contact the editorial team, please email ALBEditor@thomsonreuters.com.